A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.
An article from
News roundup
A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.
Published Aug. 26, 2026
Getty Images
Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical C
Akeso, Summit hail ivonescimab's biliary tract cancer win in China-only Phase 3 trial
VIDEO: Calabrese discusses compounded drugs, US probe into Chinese clinical trials
